Nombre del producto:3,5-Bis(trifluoromethyl)benzyl Alcohol

IUPAC Name:[3,5-bis(trifluoromethyl)phenyl]methanol

CAS:32707-89-4
Fórmula molecular:C9H6F6O
Pureza:98%
Número de catálogo:CM115974
Peso molecular:244.14

Unidad de embalaje Stock disponible Precio($) Cantidad
CM115974-100g in stock ŹǪ
CM115974-500g in stock ľǪľ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :32707-89-4
Fórmula molecular:C9H6F6O
Punto de fusión:-
Código de sonrisas:FC(C1=CC(C(F)(F)F)=CC(CO)=C1)(F)F
Densidad:
Número de catálogo:CM115974
Peso molecular:244.14
Punto de ebullición:173.9°C at 760 mmHg
Nº Mdl:MFCD00009907
Almacenamiento:Store at room temperature.

Category Infos

Fluorinated Compounds
Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

Column Infos

Alcohols
Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.
Tradipitant
Vanda announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years and to be accepted for review by the FDA for gastroparesis in over 30 years. Tradipitant is an NK-1R antagonist. It works by blocking substance P, a small signaling molecule. Tradipitant can affect gastric peristalsis and directly affect neurotransmission in the brain area responsible for nausea and vomiting, thus playing a role in the treatment of symptoms of gastroparesis. This NDA is mainly based on the results of the Phase II VP-VLY-686-2301 study and the Phase III VP-VLY-686-3301 study.

Related Products